The best aortic prostheses have been debated for decades. The introduction of stentless aortic bioprostheses was aimed at improving hemodynamics and potentially the durability of aortic bioprostheses. Despite the good short-and long-term outcomes after implantation of stentless aortic bioprostheses, their use remains limited owing to the technically demanding implantation techniques. Nevertheless, stentless aortic bioprostheses might be of special benefit in certain indications, where they could be a valuable addition to the surgical armamentarium.
Introduction
Aortic homografts were the first successful stentless bioprostheses used to treat aortic valve pathologies in the early 1960s. 1 However, the limited availability and difficult implantation technique limited their use in the clinical practice. As an alternative, stentless and stented xenografts were introduced in the middle of the 1960s, [2] [3] [4] with limited success due to poor tissue fixation, until Carpentier and colleagues 5 introduced glutaraldehyde fixation of xenografts in the late 1960s, which is still used today. Stentless bioprostheses were originally introduced in a trial to fulfill the criteria of an ideal replacement valve proposed by Harken; 6 these criteria are still regarded as the basis for judging modern prosthetic valve performance. These criteria include prolonged durability, low thrombogenicity, maximum effective orifice area, low inherent gradient, and ease of implantation. The use of stentless aortic bioprostheses was revived in 1986 by David and colleagues 7 at Toronto General Hospital. Thereafter, wide use of stentless aortic bioprostheses was established around the world in the early 1990s. 8 The design of stentless aortic bioprostheses was aimed at optimizing hemodynamics by avoiding the obstructive effect of the stent and sewing cuff of all conventional stented aortic bioprostheses. This resulted in better hemodynamics and transvalvular gradients, which were shown in early results of the use of stentless aortic bioprostheses. 1, 10 Moreover, the design of stentless aortic bioprostheses was seen to be beneficial in preventing turbulence across the valve, consequently decreasing leaflet stress and structural valve destruction, which are implicated in the limited durability of all biological valves. 11 
Methods
For the purpose of this review, a systematic search of the United States National Library of Medicine's PubMed and MEDLINE databases until February 2016 was conducted using the key words ''stentless aortic valve'' and ''stentless aortic bioprosthesis''. We also checked related articles and references in the reference lists of the relevant articles. From more than 700 articles, only those highlighting a special indication for stentless aortic bioprostheses were considered.
Types of stentless aortic bioprostheses
Stentless bioprostheses can be divided into 3 generations (Table 1 ). The first generation includes stentless porcine bioprostheses, introduced as either scalloped porcine bioprostheses (St. Jude Toronto SPV, St. Jude Biocor, Koehler Elan, Labcor, and CryoLife-O'Brien) or complete porcine aortic roots (Medtronic Freestyle, illustrated in Figure 1 , Edwards Prima Plus, St. Jude SVP Root, and Koehler Elan Root). The valves of this generation have been the most widely used and studied so far. The second generation includes porcine valves that need only one suture line along the aortic annulus and simple fixation of the 3 commissures. The Shelhigh Super Stentless valve is one of the second generation valves. The third generation includes stentless pericardial bioprosthesis such as the bovine Sorin Pericarbon Freedom, Sorin Pericarbon Freedom Solo, Sorin Solo Smart (Figure 2) , and the equine 3F Therapeutics valve. Despite promising results with the newer valve types, they have only been used in limited centers, in relatively small numbers of patients, and without sufficient long-term followup data.
Surgical techniques of stentless valve implantation
Stentless valves can be implanted using several techniques. The subcoronary technique is most commonly used, where the prosthesis is fixed underneath the coronary ostia, mostly using two suture lines. Other techniques include the modified subcoronary, total root, and root inclusion techniques. These techniques have been described elsewhere and are not the main focus of our work.
Challenges facing the use of stentless valves
The implantation of stentless bioprostheses is technically demanding and time-consuming. This overshadows their safety and good short-and long-term results. [12] [13] [14] Many studies have demonstrated their favorable hemodynamic performance; 15, 16 however, other studies failed to confirm these results, although they were not seen as inferior to stented bioprostheses. 17, 18 Early studies showed that the difficulty in implanting stentless bioprostheses was not associated with increased postoperative risk compared to mechanical or stented bioprostheses. 12, 19, 20 However, unanticipated higher postoperative gradients were reported. 16, 21 These early reports were further studied to identify the factors leading to compromised postoperative results, and a better mean postoperative gradient correlated with the surgeon's experience. 22, 23 On the other hand, excellent results were reported from centers with a higher volume, even in more complicated patients. 24, 25 Nevertheless, the percentage of stentless bioprostheses among all bioprostheses remained low (15% in Germany for example). 23 Although the total root technique is reported to result in the best postoperative gradients without increased postoperative risks, 26 its use is much more limited than the subcoronary technique owing to the perceived technical difficulty and longer ischemic time.
Stentless versus stented bioprosthesis
Despite the theoretical advantages of stentless bioprostheses, studies comparing them to stented bioprostheses have had conflicting findings; some showed better survival, 28 which could not be proven in other studies. 29 However, the non-inferiority of stentless bioprostheses compared to stented bioprostheses is widely accepted. 27 Many studies and meta-analyses have confirmed that the favorable results of stentless valves are obvious at 6 months, particularly regarding left ventricular mass regression, mean gradient, and effective orifice area index. At 12 months, these results were not different. 15 Additional advantages have been reported with stentless bioprostheses in specific groups of patients, such as those with decreased left ventricular function or smaller implanted valve sizes. 28, 30 Moreover, coronary flow and coronary flow reserve were proven to be higher after stentless aortic valve replacement, due to the more physiologic configuration of the sinuses of Valsalva, with less turbulence. 31 However, the competitiveness of stentless valves is very difficult to establish in clinical practice. On the introduction of stentless valves in the late 1980s, there were already published results of 15 years of experience with stented valves. 31 This discrepancy in the length of experience with stented bioprostheses gives them a definite advantage.
The constant development of newer generations of both valve types makes it difficult to compare results between them. The development of fixation techniques, with or without pressure, and anti-calcification agents for stented, 33 as well as stentless valves, 9 is supposed to affect the durability of the valves, irrespective of valve type. The low proportion of stentless valves used in practice, in comparison to stented valves since their introduction, seems to add to the problem of comparability of these valves. 34 This low volume and the increased technical demand would definitely discourage the use of such valves. 35 These unresolved dilemmas led to a new concept regarding the relationship between both types of valve; a complimentary rather than a competitive relationship. 34 Stentless valves could be regarded as an augmentation of the surgical armamentarium when addressing aortic valve diseases, where their use in special situations is regarded as beneficial. 
Current indications for stentless aortic bioprostheses Infective endocarditis
Infective endocarditis is a serious and uncommon disease with an incidence of 2.4-11.6/100,000 persons per year. 37 From the surgical point of view, it constitutes a real challenge regarding the surgical anatomy and tissue quality. Perivalvular abscesses and aorto-cavitary fistulae are examples of extensive damage caused by aggressive pathogens. Radical debridement to eliminate the infected tissues in order to minimize the incidence of residual and recurrent endocarditis is a fundamental step in the surgical treatment of infective endocarditis. 38 However, the development of an abscess with extensive tissue destruction may hinder the adequate excision of diseased tissue, influencing mortality and morbidity. In such cases, it is of the outmost importance to implant a valve that can resist infection. The introduction of homografts provided an excellent option for treating these patients, allowing reconstruction of the left ventricular outflow tract, and simultaneously excluding or covering the defect left after debriding a peri-annular abscess. 39, 40 Perrotta and colleagues 41 performed a meta-analysis of 10 studies comparing aortic homografts to stentless bioprostheses, and demonstrated that stentless bioprostheses are associated with low reinfection rates, ranging from 3.7% to 8.6%, as well as good hemodynamic parameters comparable to cryopreserved homografts. The availability of stentless bioprostheses is a great advantage over homografts. Many stentless bioprostheses allow their use in various surgical techniques. In patients with less extensive aortic root abscesses, they can be implanted in a subcoronary position, whereas with a more extensive infection where the abscess is localized at or above the level of the annulus, the bioprosthesis can be inserted as a total root replacement. 41 Musci and colleagues 42 studied a series of 255 patients who received Shelhigh stentless bioprostheses for aortic valve endocarditis. They reported an overall reinfection rate of 8.6%, with freedom from reinfection at 5 years of 83%, and 5-year survival of 46.8%. Schneider and colleagues 43 studied 55 patients who received Freestyle valves for aortic valve endocarditis. They reported 11% early mortality and 5-year survival of 70%; only one patient required reoperation 2.3 years postoperatively due to recurrence. Similarly, Sponga and colleagues 44 reported a series of 40 patients undergoing aortic valve replacement using Sorin Pericarbon Freedom stentless bioprostheses and reconstruction of the left ventricular outflow tract after destructive aortic valve endocarditis. They demonstrated 10% hospital mortality and 76% 5-year survival, without any reoperation. The Biocor stentless bioprostheses showed similar results in patients with aortic valve endocarditis. 45 On the other hand, use of the Freestyle total root replacement in cases of extensive destruction of peri-annular tissues after native or prosthetic aortic valve endocarditis showed encouraging results in small groups of patients, interestingly, without recurrence in the follow-up period. 46, 47 This was attributed to radical debridement and exclusion of the abscess cavities as well as the intrinsic properties of Freestyle bioprostheses, such as the fixation process and anti-calcification treatment. 47 Heinz and colleagues 48 reported the long-term outcomes after Freestyle total root replacement for complex aortic valve endocarditis in 32 patients (median age, 61 years). The 5-year survival was 62%, and 5-year freedom from short-and long-term cardiac events was 56%. The aforementioned studies had small numbers of patients due to the fortunately uncommon incidence of the disease. Nevertheless, the good results, versatility of implantation techniques, and availability of stentless bioprostheses should encourage their use in such a demanding subset of patients.
Small aortic root
Patients with a small aortic root are at risk of patientprosthesis mismatch, with a significant increase in allcause and cardiac-related mortality in mid-and long-term follow-up, as well as impaired quality of life. 49 Aortic valve replacement with aortic root enlargement is a possible solution; however, this has been associated with increased perioperative morbidity and mortality. 50 Use of a stentless aortic bioprosthesis has the potential to decrease patient-prosthesis mismatch. Avoiding a stent allows the implantation of a larger bioprosthesis, reducing intraluminal obstruction, and consequently increasing the effective orifice area and providing better hemodynamic function. It has been reported that for a given annulus size it is possible to implant a nonstented bioprosthesis one-size larger than a stented valve. 51 Moreover, several experimental studies have shown that the effective orifice areas of stentless valves are significantly larger than their respective stented valves. 52, 53 Ali and colleagues 54 showed a trend towards improved hemodynamic performance of stentless valves in a small subgroup of patients with smaller aortic annuli or preoperative ventricular impairment. The consensus statement of the International Society of Minimally Invasive Cardiothoracic Surgery recommends full root replacement with a stentless bioprostheses for treatment of a small aortic root (<21 mm) as an alternative to root enlargement procedures (class I, level C). 36, 55 Other reports showed that the use of a total root allowed oversizing (1-2-sizes larger than the measured aortic annulus using Freestyle sizers), with overall 30-day mortality of 5%, and overall survival at 5 and 9 years of 74.4% and 53.6%, respectively. The rates of freedom from reoperation, structural valve deterioration, prosthetic valve endocarditis, thromboembolic and major bleeding events at 9 years were 94.6%, 94.6%, 94.3%, 87.5%, and 95.2%, respectively. 56 
Aneurysm of the aortic root
Aortic root replacement using a mechanical composite graft with reimplantation of the coronary ostia (modified Bentall operation) has remained the gold standard for treatment of aortic root pathologies for decades. However, many other biological alternatives have been introduced to avoid the need for lifelong oral anticoagulation. 57 A stentless aortic bioprosthesis as a total root is a good option to replace the aortic valve and root, avoiding the need for a tube graft in the case of localized aortic root aneurysm, providing a large aortic opening area, maintaining the morphology of the sinuses of Valsalva, and affording the other advantages of bioprostheses. 56 McCarthy and colleagues 58 evaluated patients receiving a total root stentless porcine bioprosthesis, pericardial, or mechanical composite root. They reported that the stentless porcine bioprosthesis had the lowest gradients beyond 1 year among all root replacements, with significantly better ventricular remodelling than mechanical composite roots. Even in the setting of acute type A aortic dissection, total root porcine bioprostheses achieved satisfactory early and midterm clinical outcomes. 59 Nevertheless, there have been a few reported cases of rupture of the sinuses of xenograft prostheses years after their implantation. 60, 61 Through our experience with Freestyle bioprostheses, we recommend transfixion ligation of the porcine coronary ostia using 5/0 polypropylene, because the full root is normally delivered with only simple ligation of the ostia, which can be displaced later, causing rupture or pseudoaneurysm of the aortic root. Furthermore, avoiding passing the needle for transfixion underneath this ligature must be emphasized, because the porcine aortic sinus near the coronary ostia is weaker than elsewhere, which has also be noted in humans.
Athletes and active patients
On exercise, flow through the left ventricular outflow tract increases, and the gradient across the aortic valve may increase if the left ventricular outflow tract does not dilate to accommodate the increased flow. In-vitro testing of bioprosthetic and mechanical valves has demonstrated progressively higher, and presumably more obstructive, gradients as cardiac output increases. 62 This has been clinically supported by the work of Silberman and colleagues 63 who compared the hemodynamic performance of stentless aortic bioprostheses and stented mechanical valves with normal native aortic valves at rest and exercise. They demonstrated that stentless bioprostheses behave in a similar way to normal aortic valves, showing almost no increase in gradient on exercise, whereas both mechanical and stented biological valves showed increased gradients on exercise, suggesting that these valves obstruct blood flow. Fries and colleagues 64 compared gradients across 23-mm stentless and 23-mm stented bioprostheses. They demonstrated the similarity of stentless bioprostheses to healthy native valves, showing no increase in gradient on exercise, whereas the gradient increased significantly with increasing cardiac output in the stented group. On the other hand, the 3rd generation of stented bioprostheses might be promising in this subset of patients. Recently published data showed similarly excellent hemodynamics at rest and exercise after implantation of 3rd generation stented bioprostheses compared to stentless bioprostheses. 65, 66 Reoperative aortic valve replacement Stentless aortic bioprostheses can be a good option in cases of reoperative aortic valve replacement, either after stented or stentless aortic valve replacement. The explantation of the aortic prosthesis is frequently associated with various degrees of damage to the aortic annulus and sinuses. 67 Weakness in the ''foot-print'' area of the stented aortic prosthesis in the aortic wall, especially after implantation of a supraannular stented prosthesis or subcoronary stentless bioprosthesis, is not uncommon. Unfortunately, attempts to repair these lesions are frequently associated with narrowing of the area of the aortic annulus, leading to the implantation of smaller prostheses in many cases, with deleterious effects regarding transvalvular gradients and left ventricular mass regression. Therefore, the implantation of a stentless bioprosthesis gives the surgeon many options to repair these lesions or exclude weak points in the aortic sinus without sacrificing much in terms of transvalvular gradients and left ventricular mass regression. Unfortunately, little information is available on comparisons of stentless bioprostheses to other valve types in reoperative aortic valve replacement. However, the presumed technical difficulties of implanting stentless aortic bioprostheses (Freestyle) in the setting of reoperations was compared to stented aortic bioprostheses in two groups of patients. No significant differences were noted between the 2 groups regarding mortality, myocardial infarction, rethoracotomy, crossclamp or operative time, but an uneven distribution of patients in favor of the stented group was noted, with a two-fold higher preoperative incidence of concomitant surgeries and endocarditis in the stentless group. 68 On the other hand, the technical difficulty of reoperative aortic valve replacement after implantation of stentless valves differs according to the type of the stentless valve, the technique of implantation, and the pathology of valve deterioration.
Through our experience with Freestyle valves, we found that reoperation after a subcoronary implanted Freestyle valve is technically easier than after a stented bioprosthesis, because in most cases, one of the leaflets is torn and can be easily excised. Nevertheless, we recommend full explantation of the whole valve because there is only slight cohesion or calcification between the valve and the aorta, probably due to the anti-calcification treatment of the Freestyle valves. These findings are supported by the results of Deeb and colleagues 69 showing no mortality in 10 patients operated on after Freestyle implantation, mostly after endocarditis, describing no calcification in the whole group. On the contrary, aortic valve repeat replacement after total root implantation is technically more demanding due to adhesions of the bioprosthetic aortic root and possibility kinking, tension, or injury to the coronaries. Accordingly, it may be prudent to implant the next valve into the existing Freestyle valve whenever possible. However, our own experience is limited as we only had to reoperate on 2 patients with endocarditis early after a total root procedure, and the entire prosthetic material was removed. Therefore, we recommend the preparation of larger coronary buttons during the first total root replacement, to facilitate a later reoperation. Borger and colleagues 67 studied 57 patients with stentless valves, who underwent redo aortic valve replacement; 47 of them had Toronto stentless porcine valves at the time of the first operation. They demonstrated a higher mortality rate (11%) and more technical difficulty, especially after endocarditis or within one year after the first operation. Moreover, they reported the frequent need for total root implantation (63%) and reconstruction at the base of the heart to repair defects left after difficult extraction of the stentless bioprostheses.
Patients requiring concomitant aortic valve and mitral valve surgery
The aortic and mitral valves are coupled via fibrous tissue. 70 Simultaneous dynamic analysis of both valves throughout the cardiac cycle has demonstrated synchronous and reciprocal dynamic behavior. 71 In addition, Veronesi and colleagues 72 demonstrated the effect of mitral valve repair or replacement, being responsible for a smaller aortic orifice area and reduced dynamics due to a constrictive effect of the annuloplasty ring or mitral prosthesis. Consequently, constraints imposed by valvular repair or replacement of one valve may lead to undesired and unexpected changes in the dynamics of the other valve, simultaneously altering mitral-aortic coupling. Therefore, the implantation of a stentless aortic bioprosthesis in concomitant mitral valve surgery might be a better option than a stented bioprosthesis.
Patients on hemodialysis
Patients on regular hemodialysis are at higher risk of early calcification of their aortic bioprosthesis. 73 Nevertheless, in 2012, the European Society of Cardiology and the European Association for CardioThoracic Surgery made a IIa recommendation on the use aortic bioprostheses in hemodialysis patients because the durability of aortic bioprostheses exceeds the patients' life-expectancy. 74 However, with advances in medical services, the survival of end-stage renal disease patients has improved over recent decades. 75 Thus a more durable bioprosthesis would be required. In a recent study of 2 groups of patients on regular hemodialysis, who received either stentless Freestyle or stented aortic bioprostheses, the midterm follow-up (mean 36 months) showed that patients in the Freestyle group had less calcification or sclerosis of their bioprostheses, inferring that the Freestyle aortic bioprosthesis might be more resistant to calcification in hemodialysis patients. 76 
Conclusions
Factors influencing the choice of valve for aortic valve replacement have been traditionally seen as patient age, body surface area, aortic valve pathology, and/or annular size. Since the introduction of stentless valves, there has been an increasingly higher awareness of other lessrecognized patient characteristics, such as small aortic root, associated aortic aneurysm, infective endocarditis, reoperation, expected postoperative activity, concomitant operations, and the risk of early calcification. These should be given similar attention because they greatly influence the surgical planning and, consequently, the outcome. The variety of valve types has allowed surgeons like never before, to treat valve diseases with great flexibility. This applies to other newly developed stentless valves, such as percutaneously implantable valves, which are increasingly used in high-risk patients. The continuous development of these valves will encourage the use of bioprostheses in younger patients, allowing them to receive their second aortic valve replacement percutaneously as a valve-invalve. 77 Although this might be challenging due to the lack of anatomic markers and the risk of coronary artery occlusion, satisfactory positioning and outcomes are possible in most cases. 78 One of the greatest challenges facing the future of stentless valves is adequate surgical experience and training. While homografts are constantly in a state of undersupply, this is not the case with stentless valves. A broader consensus on how to treat specific aortic valve diseases and better training programs are crucial to the existence of such stentless valves, with a consequently great impact on the variety of surgical tools available to treat aortic valve diseases.
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